Characteristics of cohort, by survival status
| Characteristics . | Survivors (n = 184) . | Died during follow-up (n = 29) . | Died during first iTTP episode (n = 9) . | Total cohort (N = 222) . | P* . |
|---|---|---|---|---|---|
| Female sex | 72.8% | 55.2% | 66.7% | 70.3% | .053 |
| Race | .070 | ||||
| White | 44.6% | 65.5% | 33.3% | 46.8% | |
| African American | 53.8% | 31.0% | 44.4% | 50.5% | |
| Other/unknown | 1.6% | 3.4% | 22.2% | 2.7% | |
| Age (y), median (IQR) | 41 (28, 55) | 42 (31,50) | 44 (35, 77) | 42 (29, 55) | .451 |
| Total no. of iTTP episodes, median (IQR) | 1 (1,3) | 3 (1,5) | 1 (1,1) | 1 (1,3) | <.001 |
| Comorbidities | |||||
| Hypertension | 48.9% | 62.1% | 66.7% | 51.4% | .188 |
| Diabetes | 23.4% | 31.0% | 33.3.% | 24.8% | .372 |
| Obesity (BMI > 30) | 37.5% | 27.6% | 33.3% | 35.0% | .302 |
| Hyperlipidemia | 23.9% | 24.1% | 11.1% | 23.4% | .979 |
| Atrial fibrillation | 7.1% | 6.9% | 11.1% | 7.2% | .974 |
| Systemic lupus erythematosus | 9.8% | 6.9% | 0.0% | 9.0% | .620 |
| CKD | 19.0% | 48.3% | 11.1% | 22.5% | .001 |
| Average remission ADAMT13 activity, median (IQR) | 63.2 (42.9, 82.1) | 39.0 (23.9, 64.0) | n/a | 61.2 (37.9, 78.6) | .010 |
| Follow-up time (y), median (IQR) | 4.8 (0.7, 11.8) | 5.3 (0.8,8.0) | n/a† | 4.5 (0.4, 11.5) | .975 |
| Characteristics . | Survivors (n = 184) . | Died during follow-up (n = 29) . | Died during first iTTP episode (n = 9) . | Total cohort (N = 222) . | P* . |
|---|---|---|---|---|---|
| Female sex | 72.8% | 55.2% | 66.7% | 70.3% | .053 |
| Race | .070 | ||||
| White | 44.6% | 65.5% | 33.3% | 46.8% | |
| African American | 53.8% | 31.0% | 44.4% | 50.5% | |
| Other/unknown | 1.6% | 3.4% | 22.2% | 2.7% | |
| Age (y), median (IQR) | 41 (28, 55) | 42 (31,50) | 44 (35, 77) | 42 (29, 55) | .451 |
| Total no. of iTTP episodes, median (IQR) | 1 (1,3) | 3 (1,5) | 1 (1,1) | 1 (1,3) | <.001 |
| Comorbidities | |||||
| Hypertension | 48.9% | 62.1% | 66.7% | 51.4% | .188 |
| Diabetes | 23.4% | 31.0% | 33.3.% | 24.8% | .372 |
| Obesity (BMI > 30) | 37.5% | 27.6% | 33.3% | 35.0% | .302 |
| Hyperlipidemia | 23.9% | 24.1% | 11.1% | 23.4% | .979 |
| Atrial fibrillation | 7.1% | 6.9% | 11.1% | 7.2% | .974 |
| Systemic lupus erythematosus | 9.8% | 6.9% | 0.0% | 9.0% | .620 |
| CKD | 19.0% | 48.3% | 11.1% | 22.5% | .001 |
| Average remission ADAMT13 activity, median (IQR) | 63.2 (42.9, 82.1) | 39.0 (23.9, 64.0) | n/a | 61.2 (37.9, 78.6) | .010 |
| Follow-up time (y), median (IQR) | 4.8 (0.7, 11.8) | 5.3 (0.8,8.0) | n/a† | 4.5 (0.4, 11.5) | .975 |